ExaWizards Inc.

ExaWizards and ExaMD Present Findings from a Wearable Device Study on Breast Cancer Patients—A Joint Research Project with Kansai Medical University, Daiichi Sankyo, and Others—at the American Society of Clinical Oncology “ASCO 2026” ‐Aiming to develop new digital AI healthcare services based on the analysis results‐

ExaWizards Launches Company Providing AI-Driven System Development and Platform Services, Exa Frontier Edge -Designing AI-first organizations and AI agent–driven development to create “AI-native SI” that transforms IT service speed and cost-

ExaWizards’ exaBase Generative AI for Governments Adopted by 25 Prefectural Governments (53% Nationwide) and Expanding — Utilized by over 200 government agencies and municipalities, contributing to productivity gains —

ExaWizards Announces “exaBase Corp IT Agent” to Support Security Checks When Deploying IT/AI Services — Eliminating AI Adoption Bottlenecks to Provide Fast and Secure Service Deployment —

ExaMD, an ExaWizards Group Company, Submits a Clinical Trial Notification for an AI-Powered Cognitive Function Diagnostic Support Application — Entering the Final Stages of Regulatory Approval Aiming for Early Approval within FY3/2027 Through an Innovative and Efficient Clinical Trial —

ExaWizards to Provide Comprehensive Support for the Kansai Transmission and Distribution DX Strategy 2026 — Partnering in business transformation across three key areas: fostering an organizational culture, developing digital talent, and building an AI agent environment —

ExaWizards and Dirbato Announce Business Alliance to Accelerate Corporate AX and AI Agent Utilization — Fusing “AI Products” and “Consulting Execution Capabilities” to Provide One-Stop Support to Improve Productivity and Solve Challenges in Japanese Companies —

Message from the CEO Updated